Evaluating preferences for profiles of glucagon-like peptide-1 receptor agonists among injection-naive type 2 diabetes patients in Japan

被引:28
|
作者
Gelhorn, Heather L. [1 ]
Bacci, Elizabeth D. [2 ]
Poon, Jiat Ling [1 ]
Boye, Kristina S. [3 ]
Suzuki, Shuichi [4 ]
Babineaux, Steven M. [3 ]
机构
[1] Evidera, Outcomes Res, Bethesda, MD USA
[2] Evidera, Seattle, WA USA
[3] Eli Lilly & Co, Global Patient Outcomes & Real World Evidence, Indianapolis, IN 46285 USA
[4] Eli Lilly Japan, Med Dev Unit Japan, Kobe, Hyogo, Japan
来源
PATIENT PREFERENCE AND ADHERENCE | 2016年 / 10卷
关键词
discrete choice experiment; patient's preference; type; 2; diabetes; GLP-1 receptor agonists; willingness to inject; DISCRETE-CHOICE EXPERIMENT; LIRAGLUTIDE; MELLITUS;
D O I
10.2147/PPA.S109289
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective: The objective of this study was to use a discrete choice experiment (DCE) to estimate patients' preferences for the treatment features, safety, and efficacy of two specific glucagon-like peptide-1 receptor agonists, dulaglutide and liraglutide, among patients with type 2 diabetes mellitus (T2DM) in Japan. Methods: In Japan, patients with self-reported T2DM and naive to treatment with self-injectable medications were administered a DCE through an in-person interview. The DCE examined the following six attributes of T2DM treatment, each described by two levels: "dosing frequency", "hemoglobin A1c change", "weight change", "type of delivery system", "frequency of nausea", and "frequency of hypoglycemia". Part-worth utilities were estimated using logit models and were used to calculate the relative importance (RI) of each attribute. A chi-square test was used to determine the differences in preferences for the dulaglutide versus liraglutide profiles. Results: The final evaluable sample consisted of 182 participants (mean age: 58.9 [standard deviation = 10.0] years; 64.3% male; mean body mass index: 26.1 [standard deviation = 5.0] kg/m(2)). The RI values for the attributes in rank order were dosing frequency (44.1%), type of delivery system (26.3%), frequency of nausea (15.1%), frequency of hypoglycemia (7.4%), weight change (6.2%), and hemoglobin A1c change (1.0%). Significantly more participants preferred the dulaglutide profile (94.5%) compared to the liraglutide profile (5.5%; P<0.0001). Conclusion: This study elicited the preferences of Japanese T2DM patients for attributes and levels representing the actual characteristics of two existing glucagon-like peptide-1 receptor agonists. In this comparison, dosing frequency and type of delivery system were the two most important characteristics, accounting for >70% of the RI. These findings are similar to those of a previous UK study, providing information about patients' preferences that may be informative for patient-clinician treatment discussions.
引用
收藏
页码:1337 / 1348
页数:12
相关论文
共 50 条
  • [31] Advantages of glucagon-like peptide-1 receptor agonists in the treatment of patients with type 2 diabetes mellitus: A review
    Demidova, Tatiana Yu.
    Titova, Victoria V.
    Izmaylova, Maryam Ya.
    TERAPEVTICHESKII ARKHIV, 2023, 95 (10) : 876 - 880
  • [32] Association between Glucagon-like Peptide-1 Receptor Agonists and the Risk of Glaucoma in Individuals with Type 2 Diabetes
    Niazi, Siar
    Gnesin, Filip
    Thein, Anna-Sophie
    Andreasen, Jens R.
    Horwitz, Anna
    Mouhammad, Zaynab A.
    Jawad, Baker N.
    Niazi, Zia
    Pourhadi, Nelsan
    Zareini, Bochra
    Meaidi, Amani
    Torp-Pedersen, Christian
    Kolko, Miriam
    OPHTHALMOLOGY, 2024, 131 (09) : 1056 - 1063
  • [33] Effects of glucagon-like peptide-1 receptor agonists on major coronary events in patients with type 2 diabetes
    Guo, Xueyuan
    Sang, Caihua
    Tang, Ribo
    Jiang, Chenxi
    Li, Songnan
    Liu, Nian
    Long, Deyong
    Du, Xin
    Dong, Jianzeng
    Ma, Changsheng
    DIABETES OBESITY & METABOLISM, 2023, 25 : 53 - 63
  • [34] Glucagon-like peptide-1 receptor agonist prescribing patterns in adolescents with type 2 diabetes
    Bensignor, Megan O.
    Wolf, Jack M.
    Rudser, Kyle D.
    Kelly, Aaron S.
    Arslanian, Silva
    DIABETES OBESITY & METABOLISM, 2022, 24 (07) : 1380 - 1384
  • [35] Glucagon-like peptide-1 receptor agonists and type 1 diabetes: a potential game changer?
    Resnick, Ortal
    Bril, Fernando
    Beauchamp, Giovanna
    FRONTIERS IN ENDOCRINOLOGY, 2025, 15
  • [36] Use of Glucagon-Like Peptide-1 Receptor Agonists Does Not Increase the Risk of Cancer in Patients with Type 2 Diabetes Mellitus
    Kim, Mijin
    Kim, Seung Chan
    Kim, Jinmi
    Kim, Bo Hyun
    DIABETES & METABOLISM JOURNAL, 2025, 49 (01) : 49 - 59
  • [37] DIABETES AND OBESITY. THE ROLE OF AGONISTS GLUCAGON-LIKE PEPTIDE-1 OF IN THE TREATMENT OF TYPE 2 DIABETES
    Petunina, Nina A.
    Telnova, Milena E.
    DIABETES MELLITUS, 2018, 21 (04): : 293 - 300
  • [38] Glucagon-Like Peptide-1 Receptor Agonists Reduction in Stroke Type 2 DM Patients
    Alhawyan, Fatmah Salem
    Althobaiti, Mohammed Adel
    Alnami, Hashim Yahya
    Allahafi, Hadeel Ibrahim
    Almalky, Ayman Jamaan
    Al Johani, Sultan Ahmed
    Shiban, Rokayah Hussain
    Saddah, Mohammed Ahmed
    Alamrah, Hussam Mohammed
    Aljuhani, Moayad Zeyad
    Alfallaj, Ebtehal Hamid
    INTERNATIONAL JOURNAL OF PHARMACEUTICAL AND PHYTOPHARMACOLOGICAL RESEARCH, 2020, 10 (05): : 122 - 128
  • [39] Glucagon-like peptide-1 receptor agonists and kidney outcomes
    MacIsaac, Richard J.
    Trevella, Philippa
    Ekinci, Elif I.
    JOURNAL OF DIABETES, 2024, 16 (10)
  • [40] Comparative Outcomes of Glucagon-Like Peptide-1 Receptor Agonists to Dipeptidyl Peptidase 4 Inhibitors in Patients With Heart Failure and Type 2 Diabetes
    Kishimori, Takefumi
    Kato, Takao
    Wada, Atsuyuki
    Tani, Akira
    Yamaji, Ryosuke
    Koike, Jumpei
    Iwasaki, Yoshihiro
    Matsumoto, Takehiro
    Yagi, Takafumi
    Okada, Masaharu
    JOURNAL OF THE AMERICAN HEART ASSOCIATION, 2025, 14 (04):